Erlotinib for the treatment of brain metastases in non-small cell lung cancer

References

• Ahluwalia MS, Vogelbaum MV, Chao ST, Mehta MM, Brain metastasis and treatment. F1000Prime Rep. 2014;6:114. PubMed PMID: 25580268. Pubmed Central PMCID: 4251415.
   PubMedGoogle Scholar
• Ali A, Goffin JR, Arnold A, et al. Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases. Curr Oncol. 2013 Aug;20(4):e300–6. PubMed PMID: 23904768. Pubmed Central PMCID: 3728058.
   PubMed Web of Science ®Google Scholar
• Jamal-Hanjani M, Spicer J. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain. Clin Cancer Res. 2012 Feb 15;18(4):938–944. PubMed PMID: 22167408.
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011 Mar-Apr;61(2):69–90. PubMed PMID: 21296855.
   PubMed Web of Science ®Google Scholar
• Lagerwaard FJ, Levendag PC, Nowak PJ, et al. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys. 1999 Mar 1;43(4):795–803. PubMed PMID: 10098435.
   PubMed Web of Science ®Google Scholar
• Langer CJ, Mehta MP. Current management of brain metastases, with a focus on systemic options. J Clin Oncol. 2005 Sep 1;23(25):6207–6219. PubMed PMID: 16135488.
   PubMed Web of Science ®Google Scholar
• Lin X, DeAngelis LM. Treatment of brain metastases. J Clin Oncol. 2015 Oct 20;33(30):3475–3484. PubMed PMID: 26282648.
   PubMed Web of Science ®Google Scholar
• Gaspar LE, Scott C, Murray K, et al. Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):1001–1006. PubMed PMID: 10863071.
   PubMed Web of Science ®Google Scholar
• Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2012;30(4):419–425. PubMed PMID: 22203767. Pubmed Central PMCID: 3269967.
   PubMed Web of Science ®Google Scholar
• Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010 Aug 19;363 (8): 733–742. PubMed PMID: 20818875.
   PubMed Web of Science ®Google Scholar
• Galicich JH, French LA. Use of dexamethasone in the treatment of cerebral edema resulting from brain tumors and brain surgery. Am Pract Dig Treat. 1961 Mar;12:169–174. PubMed PMID: 13703073.
   PubMedGoogle Scholar
• Sirven JI, Wingerchuk DM, Drazkowski JF, et al. Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc. 2004 Dec;79(12):1489–1494. PubMed PMID: 15595331.
   PubMed Web of Science ®Google Scholar
• Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322(8):494–500. PubMed PMID: 2405271.
   PubMed Web of Science ®Google Scholar
• Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol. 1993;33(6):583–590. PubMed PMID: 8498838.
   PubMed Web of Science ®Google Scholar
• Siomin VE, Vogelbaum MA, Kanner AA, et al. Posterior fossa metastases: risk of leptomeningeal disease when treated with stereotactic radiosurgery compared to surgery. J Neurooncol. 2004 Mar-Apr;67(1–2):115–121. PubMed PMID: 15072456.
   PubMed Web of Science ®Google Scholar
• Borgelt B, Gelber R, Larson M, et al. Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: final results of the first two studies by the radiation therapy oncology group. Int J Radiat Oncol Biol Phys. 1981 Dec;7(12):1633–1638. PubMed PMID: 6174490.
   PubMed Web of Science ®Google Scholar
• Murray KJ, Scott C, Greenberg HM, et al. A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the radiation therapy oncology group (RTOG) 9104. Int J Radiat Oncol Biol Phys. 1997;39(3):571–574. PubMed PMID: 9336134.
   PubMed Web of Science ®Google Scholar
• Aoyama H, Tago M, Kato N, et al. Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys. 2007;68(5):1388–1395. PubMed PMID: 17674975.
   PubMed Web of Science ®Google Scholar
• Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009;10(11):1037–1044. PubMed PMID: 19801201.
   PubMed Web of Science ®Google Scholar
• Sahgal A, Aoyama H, Kocher M, et al. Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: individual patient data meta-analysis. Int J Radiat Oncol Biol Phys. 2015;91(4):710–717. PubMed PMID: 25752382.
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567–578. PubMed PMID: 16467544.
   PubMed Web of Science ®Google Scholar
• Shapiro WR, Shapiro JR. Principles of brain tumor chemotherapy. Semin Oncol. 1986 Mar;13(1):56–69. PubMed PMID: 3082012.
   PubMed Web of Science ®Google Scholar
• Greig NH, Soncrant TT, Shetty HU, et al. Brain uptake and anticancer activities of vincristine and vinblastine are restricted by their low cerebrovascular permeability and binding to plasma constituents in rat. Cancer Chemother Pharmacol. 1990;26(4):263–268. PubMed PMID: 2369790.
   PubMed Web of Science ®Google Scholar
• Eichler AF, Chung E, Kodack DP, et al. The biology of brain metastases-translation to new therapies. Nat Rev Clin Oncol. 2011 Jun;8(6):344–356. PubMed PMID: 21487419. Pubmed Central PMCID: 3259742.
   PubMed Web of Science ®Google Scholar
• Demeule M, Regina A, Jodoin J, et al. Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier. Vascul Pharmacol. 2002;38(6):339–348. PubMed PMID: 12529928.
   PubMed Web of Science ®Google Scholar
• Togashi Y, Masago K, Masuda S, et al. Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol. 2012;70(3):399–405. PubMed PMID: 22806307.
   PubMed Web of Science ®Google Scholar
• Bronte G, Rolfo C, Giovannetti E, et al. Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects. Crit Rev Oncol Hematol. 2014;89(2):300–313. PubMed PMID: 24041630.
   PubMed Web of Science ®Google Scholar
• Mahipal A, Kothari N, Gupta S. Epidermal growth factor receptor inhibitors: coming of age. Cancer Control. 2014 Jan;21(1):74–79. PubMed PMID: 24357745.
   PubMed Web of Science ®Google Scholar
• Akita RW, Sliwkowski MX. Preclinical studies with Erlotinib (Tarceva). Semin Oncol. 2003 Jun;30(3 Suppl 7):15–24. PubMed PMID: 12840797.
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123–132. PubMed PMID: 16014882.
   PubMed Web of Science ®Google Scholar
• Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380–2388. PubMed PMID: 20573926.
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11(2):121–128. PubMed PMID: 20022809.
   PubMed Web of Science ®Google Scholar
• Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735–742. PubMed PMID: 21783417.
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Chansky K, Wozniak AJ, et al. Southwest oncology group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2. J Thorac Oncol. 2008;3(9):1026–1031. PubMed PMID: 18758306. Pubmed Central PMCID: 3523698.
   PubMed Web of Science ®Google Scholar
• Goss G, Ferry D, Wierzbicki R, et al. Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status. J Clin Oncol. 2009;27(13):2253–2260. PubMed PMID: 19289623.
   PubMed Web of Science ®Google Scholar
• Niho S, Kubota K, Goto K, et al. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol. 2006 Jan 1 1;24:64–69. PubMed PMID: 16382114.
   PubMed Web of Science ®Google Scholar
• Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366(9496):1527–1537. PubMed PMID: 16257339.
   PubMed Web of Science ®Google Scholar
• Moyer JD, Barbacci EG, Iwata KK, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 1997;57(21):4838–4848. PubMed PMID: 9354447.
   PubMed Web of Science ®Google Scholar
• Pollack VA, Savage DM, Baker DA, et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther. 1999;291(2):739–748. PubMed PMID: 10525095.
   PubMed Web of Science ®Google Scholar
• Ng SS, Tsao MS, Nicklee T, et al. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol Cancer Ther. 2002 Aug;1(10):777–783. PubMed PMID: 12492110.
   PubMed Web of Science ®Google Scholar
• Higgins B, Kolinsky K, Smith M, et al. Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models. Anticancer Drugs. 2004;15(5):503–512. PubMed PMID: 15166626.
   PubMed Web of Science ®Google Scholar
• Mohamed MK, Ramalingam S, Lin Y, et al. Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer. Ann Oncol. 2005 May;16(5):780–785. PubMed PMID: 15728108.
   PubMed Web of Science ®Google Scholar
• Perez-Soler R. Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer. Clin Lung Cancer. 2004 Dec;6(Suppl 1):S20–3. PubMed PMID: 15638953.
   PubMedGoogle Scholar
• Malik SN, Siu LL, Rowinsky EK, et al. Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res. 2003;9(7):2478–2486. PubMed PMID: 12855621.
   PubMed Web of Science ®Google Scholar
• Felip E, Rojo F, Reck M, et al. A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. Clin Cancer Res. 2008;14(12):3867–3874. PubMed PMID: 18559607.
   PubMed Web of Science ®Google Scholar
• Ling J, Johnson KA, Miao Z, et al. Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers. Drug Metab Dispos. 2006;34(3):420–426. PubMed PMID: 16381666.
   PubMed Web of Science ®Google Scholar
• Sandler A. Clinical experience with the HER1/EGFR tyrosine kinase inhibitor erlotinib. Oncology (Williston Park). 2003 Nov;17(11 Suppl 12):17–22. PubMed PMID: 14682119.
   PubMedGoogle Scholar
• Siegel-Lakhai WS, Beijnen JH, Schellens JH. Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). Oncologist. 2005 Sep;10(8):579–589. PubMed PMID: 16177282.
   PubMed Web of Science ®Google Scholar
• Hamilton M, Wolf JL, Rusk J, et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res. 2006;12(7 Pt 1):2166–2171. PubMed PMID: 16609030.
   PubMed Web of Science ®Google Scholar
• Clarke JL, Pao W, Wu N, et al. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol. 2010 Sep;99(2):283–286. PubMed PMID: 20146086. Pubmed Central PMCID: PMC3973736.
   PubMed Web of Science ®Google Scholar
• Lind JS, Lagerwaard FJ, Smit EF, et al. Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1391–1396. PubMed PMID: 19289264.
   PubMed Web of Science ®Google Scholar
• Hotta K, Kiura K, Ueoka H, et al. Effect of gefitinib (‘Iressa’, ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Lung Cancer. 2004;46(2):255–261. PubMed PMID: 15474674.
   PubMed Web of Science ®Google Scholar
• Namba Y, Kijima T, Yokota S, et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases. Clin Lung Cancer. 2004;6(2):123–128. PubMed PMID: 15476598.
   PubMedGoogle Scholar
• Porta R, Sanchez-Torres JM, Paz-Ares L, et al. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J. 2011;37(3):624–631. PubMed PMID: 20595147.
   PubMed Web of Science ®Google Scholar
• Bai H, Han B. The effectiveness of erlotinib against brain metastases in non-small cell lung cancer patients. Am J Clin Oncol. 2013 Apr;36(2):110–115. PubMed PMID: 22391431.
   PubMed Web of Science ®Google Scholar
• Heon S, Yeap BY, Lindeman NI, et al. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin Cancer Res. 2012;18(16):4406–4414. PubMed PMID: 22733536. Pubmed Central PMCID: 3682221.
   PubMed Web of Science ®Google Scholar
• Gerber NK, Yamada Y, Rimner A, et al. Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma. Int J Radiat Oncol Biol Phys 2014;Jun189(2):322–329. PubMed PMID: 24679729.
   PubMed Web of Science ®Google Scholar
• Olmez I, Donahue BR, Butler JS, et al. Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and Erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain metastasis. Lung Cancer. 2010 Nov;70(2):174–179. PubMed PMID: 20207442.
   PubMed Web of Science ®Google Scholar
• Wu YL, Zhou C, Cheng Y, et al. Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803). Ann Oncol. 2013;24(4):993–999. PubMed PMID: 23129122.
   PubMed Web of Science ®Google Scholar
• Welsh JW, Komaki R, Amini A, et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol. 2013;31(7):895–902. PubMed PMID: 23341526. Pubmed Central PMCID: 3577951.
   PubMed Web of Science ®Google Scholar
• Grommes C, Oxnard GR, Kris MG, et al. “Pulsatile” high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol. 2011;13(12):1364–1369. PubMed PMID: 21865399. Pubmed Central PMCID: 3223088.
   PubMed Web of Science ®Google Scholar
• Jackman DM, Holmes AJ, Lindeman N, et al. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol. 2006 Sep20;24(27):4517–4520. PubMed PMID: 16983123.
   PubMed Web of Science ®Google Scholar
• Sperduto PW, Wang M, Robins HI, et al. A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: radiation therapy oncology group 0320. Int J Radiat Oncol Biol Phys. 2013;85(5):1312–1318. PubMed PMID: 23391814. Pubmed Central PMCID: 3740376.
   PubMed Web of Science ®Google Scholar
• Lee SM, Lewanski CR, Counsell N, et al. Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases. J Natl Cancer Inst. 2014 Jul;106(7):1–7. PubMed PMID: 25031274. Pubmed Central PMCID: 4112798.
   Google Scholar
• Nakagawa K, Kudoh S, Ohe Y, et al. Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR). J Thorac Oncol. 2012;7(8):1296–1303. PubMed PMID: 22610257.
   PubMed Web of Science ®Google Scholar
• Luo D, Ye X, Hu Z, et al. EGFR mutation status and its impact on survival of Chinese non-small cell lung cancer patients with brain metastases. Tumour Biol. 2014;35(3):2437–2444. PubMed PMID: 24197981.
   PubMed Web of Science ®Google Scholar
• Eichler AF, Kahle KT, Wang DL, et al. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro Oncol. 2010;12(11):1193–1199. PubMed PMID: 20627894. Pubmed Central PMCID: PMC3098020.
   PubMed Web of Science ®Google Scholar
• DM J, SL M, JC H, al e. Pulsed dosing of erlotinib for central nervous system (CNS) progression in EGFR-mutant non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 2013.
   Google Scholar
• DW K AZD3759, an EGFR inhibitor with blood brain barrier (BBB) penetration for the treatment of non-small cell lung cancer (NSCLC) with brain metastasis (BM): Preclinical evidence and clinical cases. ASCO Annual Meeting 2015; Abstract # 8016.
   Google Scholar
• Janne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372(18):1689–1699. PubMed PMID: 25923549.
   PubMed Web of Science ®Google Scholar
• Dh L, Ks P, B O, MH L, al. e. AZD9291 activity in patients with leptomeningeal disease from non-small cell lung cancer: a Phase I study. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. 2015;PR07.
   Google Scholar
• Hoffknecht P, Tufman A, Wehler T, et al. Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease. J Thorac Oncol. 2015;10(1):156–163. PubMed PMID: 25247337. Pubmed Central PMCID: PMC4276567.
   PubMed Web of Science ®Google Scholar
• Nonagase Y, Okamoto K, Iwasa T, et al. Afatinib-refractory brain metastases from EGFR-mutant non-small-cell lung cancer successfully controlled with erlotinib: a case report. Anticancer Drugs. 2016;27(3):251–253. PubMed PMID: 26575001.
   PubMedGoogle Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316(5827):1039–1043. PubMed PMID: 17463250.
   PubMed Web of Science ®Google Scholar
• Cipriani NA, Abidoye OO, Vokes E, et al. MET as a target for treatment of chest tumors. Lung Cancer. 2009 Feb;63(2):169–179. PubMed PMID: 18672314. Pubmed Central PMCID: PMC2659375.
   PubMed Web of Science ®Google Scholar
• Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res. 2006;12(21):6494–6501. PubMed PMID: 17085664.
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352(8):786–792. PubMed PMID: 15728811.
   PubMed Web of Science ®Google Scholar
• Tan CS, Cho BC, Soo RA. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer. Lung Cancer. 2016 Mar;93:59–68. PubMed PMID: 26898616.
   PubMed Web of Science ®Google Scholar